In short
This article discusses the ongoing clinical trials of Paclitaxel Obaluronate, also known as ONCOFID-P-B, for the treatment of bladder cancer. Specifically, the drug is being studied in patients with BCG-unresponsive Carcinoma in Situ (CIS) of the bladder, with or without Ta-T1 papillary disease. The trial aims to evaluate the efficacy and safety of this intravesical treatment option for patients who have not responded to standard therapy.
At a glance
- Drug Name
- ONCOFID-P-B (Paclitaxel Obaluronate)
- Trial Phase
- Phase III
- Condition
- BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease
- Administration
- Intravesical solution
- Primary Endpoint
- Complete Response Rate (CRR) at any time
- Key Secondary Endpoints
- Duration of Response, Progression Rate, Time to Cystectomy, Event-Free Survival, Overall Survival
- Maximum Daily Dose
- 600 mg
- Maximum Total Dose
- 21.6 g
- Treatment Period
- Up to 19 months
What is ONCOFID-P-B?
ONCOFID-P-B is a new medication being studied for the treatment of certain types of bladder cancer. It is classified as a new chemical entity, which means it's a novel drug that hasn't been previously approved for medical use. The active substance in ONCOFID-P-B is called paclitaxel obaluronate.
Medical Condition Treated
ONCOFID-P-B is being investigated for the treatment of BCG-unresponsive Carcinoma in Situ (CIS) of the bladder, with or without Ta-T1 papillary disease. This is a specific type of bladder cancer that hasn't responded to the standard treatment called BCG (Bacillus Calmette-Guérin).
To understand this better:
- Carcinoma in Situ (CIS): This is an early form of cancer that is still confined to the surface layer of the bladder.
- BCG-unresponsive: This means the cancer hasn't responded to or has come back after treatment with BCG, which is typically the first-line treatment for this type of bladder cancer.
- Ta-T1 papillary disease: These are types of bladder tumors that grow out from the bladder lining but haven't invaded deeper layers.
How ONCOFID-P-B Works
ONCOFID-P-B is a combination of two substances:
- Paclitaxel: This is a chemotherapy drug that has been used to treat various types of cancer.
- Hyaluronic acid: This is a natural substance found in the body that helps with tissue repair and hydration.
The combination of these two substances creates a unique drug that is designed to target cancer cells in the bladder more effectively than traditional chemotherapy.
How ONCOFID-P-B is Administered
ONCOFID-P-B is administered as an intravesical solution. This means the medication is delivered directly into the bladder through a catheter. This method of administration allows for a high concentration of the drug to reach the cancer cells while minimizing side effects in other parts of the body.
Current Clinical Trial
ONCOFID-P-B is currently being studied in a Phase III clinical trial. This is an advanced stage of research that aims to confirm the effectiveness and safety of the drug. The trial is called "Orion-BC" and is designed to evaluate how well ONCOFID-P-B works in patients who have not responded to standard BCG treatment.
Who is Eligible for the Treatment?
The clinical trial has specific criteria for who can participate. Some key eligibility factors include:
- Adults (18 years or older) with confirmed BCG-unresponsive CIS of the bladder
- Patients who have not responded to adequate BCG therapy
- Patients who are not suitable for or refuse radical cystectomy (surgical removal of the bladder)
- Adequate organ function and overall health status
It's important to note that there are also several exclusion criteria, such as having muscle-invasive or metastatic bladder cancer, or having certain other medical conditions.
Potential Benefits
The main goals of the ONCOFID-P-B treatment being studied are:
- To achieve a complete response (disappearance of the cancer)
- To maintain this response for as long as possible
- To prevent progression to more advanced stages of bladder cancer
- To avoid the need for radical cystectomy (removal of the bladder)
- To improve overall survival
These potential benefits are being carefully evaluated in the clinical trial.
Important Considerations
While ONCOFID-P-B shows promise, it's crucial to remember:
- This is an investigational drug still being studied, and its effectiveness and safety are not yet fully established.
- Participation in the clinical trial involves regular follow-ups and medical assessments.
- As with any medical treatment, there may be potential risks and side effects that are being carefully monitored in the trial.
- The decision to participate in a clinical trial or try a new treatment should always be made in consultation with your healthcare provider.
If you have bladder cancer and are interested in learning more about ONCOFID-P-B or the clinical trial, it's important to discuss this with your oncologist or urologist. They can provide more information and help determine if this might be an appropriate option for your specific situation.